GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Long-Term Debt

Boundless Bio (Boundless Bio) Long-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Long-Term Debt?

Boundless Bio's Long-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.


Boundless Bio Long-Term Debt Historical Data

The historical data trend for Boundless Bio's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Long-Term Debt Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Long-Term Debt
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only - - - - -

Boundless Bio  (NAS:BOLD) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Boundless Bio Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio (Boundless Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio (Boundless Bio) Headlines

From GuruFocus